CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations.
about
Pharmacogenomics in the clinicUse of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice GuidelineLong-Read Single Molecule Real-Time Full Gene Sequencing of Cytochrome P450-2D6.CYP2D6 genotyping and tamoxifen in the treatment of post-menopausal breast cancerInterpreting the CYP2D6 results from the International Tamoxifen Pharmacogenetics ConsortiumCYP2D6 genotype and tamoxifen: considerations for proper nonprospective studies.Linking estrogen-induced apoptosis with decreases in mortality following long-term adjuvant tamoxifen therapy.Simulation with cells in vitro of tamoxifen treatment in premenopausal breast cancer patients with different CYP2D6 genotypes.Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer.Biomarkers in Patients with Metastatic Breast Cancer and the PRAEGNANT Study NetworkApplication of molecular profiling in clinical trials for advanced metastatic cancers.Limited predictive value of achieving beneficial plasma (Z)-endoxifen threshold level by CYP2D6 genotyping in tamoxifen-treated Polish women with breast cancer.Boronic prodrug of 4-hydroxytamoxifen is more efficacious than tamoxifen with enhanced bioavailability independent of CYP2D6 status.Effects of Pharmacogenetics on the Pharmacokinetics and Pharmacodynamics of Tamoxifen.Depression in adolescents and young adults with cancer.Boronic prodrug of endoxifen as an effective hormone therapy for breast cancer.Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studies.Polymorphism at 19q13.41 Predicts Breast Cancer Survival Specifically after Endocrine Therapy.In vivo assessment of the metabolic activity of CYP2D6 diplotypes and alleles.ABCB1 and ABCC2 and the risk of distant metastasis in Thai breast cancer patients treated with tamoxifen.Association of CYP2C19*2 and associated haplotypes with lower norendoxifen concentrations in tamoxifen-treated Asian breast cancer patients.Breast cancer recurrence in relation to antidepressant use.Clinical Application of Pharmacogenetics: Where are We Now?Prevalence of CYP2D6*2, CYP2D6*4, CYP2D6*10, and CYP3A5*3 in Thai breast cancer patients undergoing tamoxifen treatment.Lower Breast Cancer Mortality in Patients Aged 70+ AchievableAssociation of CYP2D6*10 (c.100C>T) polymorphisms with clinical outcome of breast cancer after tamoxifen adjuvant endocrine therapy in Chinese populationApplication of Mice Humanized for CYP2D6 to the Study of Tamoxifen Metabolism and Drug-Drug Interaction with AntidepressantsChasing Mendel: five questions for personalized medicine.Molecular markers for breast cancer diagnosis, prognosis and targeted therapy.Pharmacogenomic biomarkers for personalized cancer treatment.Role of cytochrome P450 genes in breast cancer etiology and treatment: effects on estrogen biosynthesis, metabolism, and response to endocrine therapy.Pharmacogenetics and breast cancer management: current status and perspectives.Pharmacogenomics toward personalized tamoxifen therapy for breast cancer.Pharmacogenetics of drug oxidation via cytochrome P450 (CYP) in the populations of Denmark, Faroe Islands and Greenland.Personalizing chemotherapy dosing using pharmacological methods.CYP2C19*2 and CYP2C19*17 variants and effect of tamoxifen on breast cancer recurrence: Analysis of the International Tamoxifen Pharmacogenomics Consortium dataset.CYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen: results from a population-based study.The genetics of drug efficacy: opportunities and challenges.Precision Oncology Medicine: The Clinical Relevance of Patient-Specific Biomarkers Used to Optimize Cancer Treatment.Evaluating the impact of missenses mutations in CYP2D6*7 and CYP2D6*14A: does it compromise tamoxifen metabolism?
P2860
Q26782786-78D91D18-74A9-451A-BFCC-671CE3A43FA0Q28079118-BAFEA07A-7E1F-4DDB-9339-486ED6FA020CQ30711413-55802D2A-BDA4-42F2-9E43-DFAF74077AFBQ34065337-7E60DAD3-A39B-406B-9A78-D99B98DEA4D1Q34102867-304D7F63-4D59-420B-A154-AEE5BE70A4ECQ34205830-4DC33BFE-D5EE-4713-9E95-C2D8738DF6E3Q34736075-486C9A89-F8B3-4F78-AEF3-BDA52E64A442Q34914140-5FD4188B-F292-4492-BD7B-5C448EE68274Q35020403-18E45912-46B2-4B91-8DCB-FEA085D92972Q35054455-0B0418DE-6DEE-43CC-A33E-958BB94E53F1Q35102633-82F4AA5E-2938-48DC-AD85-5C3AB9E49211Q35732619-89319170-82D7-42F2-9547-D39E9BD2FF42Q35768721-FF838C1E-2C1A-45BE-87C9-6134B475CA1EQ35884159-DE83019F-3559-4477-8C83-4DC99A287E83Q35899456-56513496-33D9-4ED0-8E05-E1D24B0F48FBQ35915042-5D741EE5-9B40-4DE0-A8C2-5BCF04944342Q36047387-147A1946-BD7F-468F-804C-A057BB695054Q36071595-45441F63-E5B2-47DB-9D4F-75117D6DEFBEQ36243663-E6F8ABF1-4597-4365-825B-7A4D9A2D6AFEQ36808170-51679F07-531C-489D-82BD-08D778DAA157Q36924724-197A46F1-B695-41CC-ACAA-8C50BB303E19Q37020150-607ACBD7-E4CF-4456-B5D2-8007B5C30434Q37155053-61204188-B0C6-4775-98D1-232673C0020DQ37170578-41B77AEC-5200-46C0-9C05-167253E5D196Q37176631-34153F1D-CC22-41AB-AE16-40D58B70999AQ37228037-FC1BFF57-1C2A-430C-A60D-515773C878DAQ37540176-E094CD8B-6D56-455F-9FA4-B1F1E40A706AQ38216627-7CDE8C7A-ECE4-464D-8416-F70E0B800691Q38236904-582E5D39-F51D-4FE7-A283-011DBEDE804EQ38262008-5F5D1501-C55D-4983-9218-8351E155B68EQ38305705-5705EA8F-4243-4785-AC6D-4D0F1F39CC4FQ38358816-E9ACB606-61B7-41D5-B85D-329AA6201080Q38364888-9C758EC3-52B9-447E-9982-7BCE8A49E27AQ38365410-A2740CC9-89AF-4FFF-AB09-59761446917FQ38571728-8627AB6C-C9D2-45AE-B14A-03F487B248CDQ38629670-C61ED49F-D01D-49AD-94A7-31541CD405A3Q38668766-090E3673-AB44-418F-8FF6-4EDED174B332Q38773033-AA058C45-4FD9-40A8-AEF5-0B8E87713A71Q38838757-B5FA3A7F-8146-4345-8700-8D802BEB934FQ39864884-BD2EC0AA-3183-4674-B33E-0BCB161AD6B8
P2860
CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 23 September 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations.
@en
CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations.
@nl
type
label
CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations.
@en
CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations.
@nl
prefLabel
CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations.
@en
CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations.
@nl
P2093
P2860
P50
P356
P1476
CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations.
@en
P2093
A M Thompson
A T Nguyen
A-S Dieudonné
D A Flockhart
E Haschke-Becher
P2860
P304
P356
10.1038/CLPT.2013.186
P407
P50
P577
2013-09-23T00:00:00Z